ASKA Pharmaceutical Holdings Co.,Ltd. (4886.T)
JPY 2041.0
(-0.34%)
JPY 2041.0
(-0.34%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 31.38 Billion JPY | -3.76% |
| 2022 | 32.6 Billion JPY | -5.23% |
| 2021 | 34.4 Billion JPY | -9.63% |
| 2020 | 38.07 Billion JPY | -1.53% |
| 2019 | 38.66 Billion JPY | -0.19% |
| 2018 | 38.73 Billion JPY | 63.63% |
| 2017 | 23.67 Billion JPY | -11.04% |
| 2016 | 26.61 Billion JPY | 23.68% |
| 2015 | 21.51 Billion JPY | -3.76% |
| 2014 | 22.35 Billion JPY | 29.01% |
| 2013 | 17.32 Billion JPY | -5.93% |
| 2012 | 18.42 Billion JPY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 23.99 Billion JPY | -23.55% |
| 2024 Q2 | 24.07 Billion JPY | 0.33% |
| 2023 Q2 | 33.3 Billion JPY | 3.14% |
| 2023 FY | 31.38 Billion JPY | -3.76% |
| 2023 Q4 | 31.38 Billion JPY | -8.95% |
| 2023 Q3 | 34.46 Billion JPY | 3.5% |
| 2023 Q1 | 32.28 Billion JPY | -0.98% |
| 2022 Q3 | 36.71 Billion JPY | 7.28% |
| 2022 Q4 | 32.6 Billion JPY | -11.19% |
| 2022 FY | 32.6 Billion JPY | -5.23% |
| 2022 Q1 | 34.28 Billion JPY | -0.34% |
| 2022 Q2 | 34.22 Billion JPY | -0.18% |
| 2021 FY | 34.4 Billion JPY | -9.63% |
| 2021 Q3 | 39.12 Billion JPY | 7.18% |
| 2021 Q1 | 36.4 Billion JPY | -4.38% |
| 2021 Q4 | 34.4 Billion JPY | -12.06% |
| 2021 Q2 | 36.5 Billion JPY | 0.27% |
| 2020 Q2 | 36.37 Billion JPY | -4.0% |
| 2020 FY | 38.07 Billion JPY | -1.53% |
| 2020 Q4 | 38.07 Billion JPY | -4.09% |
| 2020 Q1 | 37.89 Billion JPY | -2.0% |
| 2020 Q3 | 39.69 Billion JPY | 9.12% |
| 2019 Q2 | 40.62 Billion JPY | -3.32% |
| 2019 Q3 | 40.57 Billion JPY | -0.14% |
| 2019 FY | 38.66 Billion JPY | -0.19% |
| 2019 Q1 | 42.02 Billion JPY | 8.48% |
| 2019 Q4 | 38.66 Billion JPY | -4.7% |
| 2018 Q4 | 38.73 Billion JPY | 6.0% |
| 2018 Q2 | 39.05 Billion JPY | 20.49% |
| 2018 Q1 | 32.41 Billion JPY | 36.9% |
| 2018 FY | 38.73 Billion JPY | 63.63% |
| 2018 Q3 | 36.54 Billion JPY | -6.42% |
| 2017 Q1 | 25.91 Billion JPY | -2.65% |
| 2017 FY | 23.67 Billion JPY | -11.04% |
| 2017 Q4 | 23.67 Billion JPY | -3.78% |
| 2017 Q3 | 24.6 Billion JPY | -2.74% |
| 2017 Q2 | 25.29 Billion JPY | -2.36% |
| 2016 Q1 | 22.49 Billion JPY | 4.52% |
| 2016 FY | 26.61 Billion JPY | 23.68% |
| 2016 Q2 | 23.72 Billion JPY | 5.47% |
| 2016 Q4 | 26.61 Billion JPY | 1.67% |
| 2016 Q3 | 26.18 Billion JPY | 10.36% |
| 2015 Q2 | 21.4 Billion JPY | 59.36% |
| 2015 Q1 | 13.42 Billion JPY | -39.93% |
| 2015 Q4 | 21.51 Billion JPY | -7.39% |
| 2015 Q3 | 23.23 Billion JPY | 8.58% |
| 2015 FY | 21.51 Billion JPY | -3.76% |
| 2014 Q4 | 22.35 Billion JPY | 7.04% |
| 2014 Q2 | 21.59 Billion JPY | 84.61% |
| 2014 Q1 | 11.69 Billion JPY | -32.49% |
| 2014 Q3 | 20.88 Billion JPY | -3.29% |
| 2014 FY | 22.35 Billion JPY | 29.01% |
| 2013 FY | 17.32 Billion JPY | -5.93% |
| 2013 Q1 | 18.03 Billion JPY | -2.12% |
| 2013 Q3 | 9.9 Billion JPY | -6.71% |
| 2013 Q4 | 17.32 Billion JPY | 74.9% |
| 2013 Q2 | 10.62 Billion JPY | -41.09% |
| 2012 Q4 | 18.42 Billion JPY | -2.7% |
| 2012 Q3 | 18.93 Billion JPY | 6.12% |
| 2012 Q2 | 17.84 Billion JPY | 0.0% |
| 2012 FY | 18.42 Billion JPY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 24.98 Billion JPY | -25.584% |
| Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.599% |
| Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 95.823% |
| Shionogi & Co., Ltd. | 164.35 Billion JPY | 80.906% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -824.336% |
| Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 26.796% |
| Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | -12.614% |
| Eisai Co., Ltd. | 494.82 Billion JPY | 93.658% |
| Morishita Jintan Co., Ltd. | 5.04 Billion JPY | -522.639% |
| Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 49.134% |
| Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | -1.781% |
| Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 21.141% |
| Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | -0.955% |
| Tsumura & Co. | 132.88 Billion JPY | 76.385% |
| Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 21.135% |
| Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | -136.001% |
| Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 88.579% |
| Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 28.935% |
| Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 55.617% |
| KYORIN Holdings, Inc. | 46.89 Billion JPY | 33.08% |
| Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | -348.108% |
| Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | -23.358% |
| SymBio Pharmaceuticals Limited | 8.14 Billion JPY | -285.415% |
| MedRx Co., Ltd | 129 Million JPY | -24226.357% |
| Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -858.92% |
| Solasia Pharma K.K. | 673 Million JPY | -4562.853% |
| Modalis Therapeutics Corporation | 645.5 Million JPY | -4761.48% |
| Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 80.865% |
| Cyfuse Biomedical K.K. | 1.01 Billion JPY | -3002.913% |
| Toho Holdings Co., Ltd. | 523.98 Billion JPY | 94.011% |
| Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | -351.373% |